Drug Discovery Today educational webinars are becoming increasingly popular. We work with leading experts from the industry, using the webinar format to generate and promote educational forums to help you in your research needs.
Archive
 |
Date: 12 September 2012,
Duration: 1 hours
|
Epigenetic targets are exciting to drug discovery scientists because they hold great potential across a wide spectrum of therapeutic areas. The field of epigenetics focuses on the investigation of enzymes that alter gene expression through modification of their target substrates, usually through the addition or removal of methyl or acetyl groups. High-throughput assays to identify agents capable of modifying the action of such enzyme targets has, in the past, proven to be challenging due to the relatively small molecular alterations in addition to the possibility of sequential modifications, leading to multiple end products. As such, high-throughput bioassays that allow the direct, concurrent quantification of multiple modification states are attractive. The RapidFire platform enables high-throughput mass spectrometric analysis of native molecules from in vitro reactions by performing on-line desalting in seconds, as opposed to HPLC, which requires minutes. Moreover, the RapidFire system can be connected to any mass spectrometer providing unparalleled versatility in reaction detection.
 |
Date: 24 August 2012,
Duration: 1 hours
|
Ultra high performance liquid chromatography (UHPLC) coupled with orthogonal acceleration hybrid quadrupole-time-of-flight (QqTOF) mass spectrometry is an emerging technique offering new strategies for the efficient screening of new chemical entities (NCE) and related molecules at the early discovery stage within the pharmaceutical industry.
 |
Date: 7 December 2011, 8am PT, 11am ET, 4pm GMT
Duration: 1 hours
|
The integration of pharmacodynamic and pharmacokinetic parameters in non clinical pharmacology studies is a key aspect in drug discovery for efficacy and safety assessment, in the particular for the translation from the non clinical to the clinical field. Modeling the profile of plasma exposure achieved with the intended therapeutic route often requires the use of intravenous infusion. In addition, in most cases infusion parameters (infusion rate, volume, duration and sequences) need to be customized to achieve the appropriate pattern of plasma drug exposure. When pharmacodynamic parameters are recorded by telemetry, the use of implantable pumps rather than external pumps is necessary to preserve the improvement in physiological data recording offered by telemetry.
 |
Date: 25 August 2011, 10.00am Shanghai Time
Duration: 1 hours
|
AB SCIEX is proud to present the 2nd installment of a Global 4-Part Live Webinar Series exploring novel and dynamic workflows for Metabolite Identification & Drug Metabolism solutions as it pertains to the 4 main stages of the drug discovery and development paradigm, Lead Discovery, Late Stage Discovery, Early Development and Late Stage Development. Part 2 of this webinar series will focus on how HRMS technology has fundamentally changed the way metabolite biotransformations are investigated in Lead Discovery.
 |
Date: 20 April 2011, 11:00 AM EST/ 16:00 GMT
Duration: 1 hours
|
AB SCIEX is proud to present the initial installment of a Global 4-Part Live Webinar Series exploring novel and dynamic workflows for Metabolite Identification & Drug Metabolism solutions as it pertains to the 4 main stages of the drug discovery and development paradigm, Lead Discovery, Late Stage Discovery, Early Development and Late Stage Development. Part 1 of this webinar series will focus on uniquely intelligent HRMS workflows for metabolite ID in Lead Discovery.
 |
Date: 25 March 2010, 1pm Eastern Daylight Time
Duration: 1 hours
|
Metabolomics, i.e. the systematic identification and quantitation of marker metabolites in a given compartment, cell, tissue or body fluid, is increasingly recognized as the most relevant approach to depicting the functional end-points of physiological and pathophysiological processes. Yet, a reliable and standardized technology platform rendering metabolomics applicable to routine diagnostics has not been in place so far.
|
Date: 24 September 2009, 6pm BST, 1pm EST
Duration: 1 hours
|
 |
Date: 30 June 2009,
Duration: 1 hours
|
In association with Matabolon.
This presentation demonstrated the utility of metabolomics in drug safety research through a case study done in collaboration with Teva Pharmaceutical Industries Ltd.